Cargando…
A Functional Variant on 9p21.3 Related to Glioma Risk Affects Enhancer Activity and Modulates Expression of CDKN2B‐AS1
Genome‐wide association studies have identified SNPs associated with glioma risk on 9p21.3, but biological mechanisms underlying this association are unknown. We tested the hypothesis that a functional SNP on 9p21.3 affects activity of an enhancer, causing altered expression of nearby genes. We cons...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519084/ https://www.ncbi.nlm.nih.gov/pubmed/34153138 http://dx.doi.org/10.1002/humu.24244 |
_version_ | 1784584376764334080 |
---|---|
author | Ali, Mourad Wagdy Patro, C. Pawan K. Devall, Matthew Dampier, Christopher H. Plummer, Sarah J. Kuscu, Cem Adli, Mazhar Lai, Rose K. Casey, Graham |
author_facet | Ali, Mourad Wagdy Patro, C. Pawan K. Devall, Matthew Dampier, Christopher H. Plummer, Sarah J. Kuscu, Cem Adli, Mazhar Lai, Rose K. Casey, Graham |
author_sort | Ali, Mourad Wagdy |
collection | PubMed |
description | Genome‐wide association studies have identified SNPs associated with glioma risk on 9p21.3, but biological mechanisms underlying this association are unknown. We tested the hypothesis that a functional SNP on 9p21.3 affects activity of an enhancer, causing altered expression of nearby genes. We considered all SNPs in linkage disequilibrium with the 9p21.3 sentinel SNP rs634537 that mapped to putative enhancers. An enhancer containing rs1537372 exhibited allele‐specific effects on luciferase activity. Deletion of this enhancer in GBM cell lines correlated with decreased expression of CDKN2B‐AS1. Expression quantitative trait loci analysis using non‐diseased brain samples showed rs1537372 to be a consistently significant eQTL for CDKN2B‐AS1. Additionally, our analysis of Hi‐C data generated in neural progenitor cells showed that the bait region containing rs1537372 interacted with the CDKN2B‐AS1 promoter. These data suggest rs1537372, a SNP at the 9p21.3 risk locus, is a functional variant that modulates expression of CDKN2B‐AS1. |
format | Online Article Text |
id | pubmed-8519084 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85190842021-10-22 A Functional Variant on 9p21.3 Related to Glioma Risk Affects Enhancer Activity and Modulates Expression of CDKN2B‐AS1 Ali, Mourad Wagdy Patro, C. Pawan K. Devall, Matthew Dampier, Christopher H. Plummer, Sarah J. Kuscu, Cem Adli, Mazhar Lai, Rose K. Casey, Graham Hum Mutat Brief Reports Genome‐wide association studies have identified SNPs associated with glioma risk on 9p21.3, but biological mechanisms underlying this association are unknown. We tested the hypothesis that a functional SNP on 9p21.3 affects activity of an enhancer, causing altered expression of nearby genes. We considered all SNPs in linkage disequilibrium with the 9p21.3 sentinel SNP rs634537 that mapped to putative enhancers. An enhancer containing rs1537372 exhibited allele‐specific effects on luciferase activity. Deletion of this enhancer in GBM cell lines correlated with decreased expression of CDKN2B‐AS1. Expression quantitative trait loci analysis using non‐diseased brain samples showed rs1537372 to be a consistently significant eQTL for CDKN2B‐AS1. Additionally, our analysis of Hi‐C data generated in neural progenitor cells showed that the bait region containing rs1537372 interacted with the CDKN2B‐AS1 promoter. These data suggest rs1537372, a SNP at the 9p21.3 risk locus, is a functional variant that modulates expression of CDKN2B‐AS1. John Wiley and Sons Inc. 2021-06-29 2021-10 /pmc/articles/PMC8519084/ /pubmed/34153138 http://dx.doi.org/10.1002/humu.24244 Text en © 2021 The Authors. Human Mutation Published by Wiley Periodicals LLC https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Brief Reports Ali, Mourad Wagdy Patro, C. Pawan K. Devall, Matthew Dampier, Christopher H. Plummer, Sarah J. Kuscu, Cem Adli, Mazhar Lai, Rose K. Casey, Graham A Functional Variant on 9p21.3 Related to Glioma Risk Affects Enhancer Activity and Modulates Expression of CDKN2B‐AS1 |
title | A Functional Variant on 9p21.3 Related to Glioma Risk Affects Enhancer Activity and Modulates Expression of CDKN2B‐AS1
|
title_full | A Functional Variant on 9p21.3 Related to Glioma Risk Affects Enhancer Activity and Modulates Expression of CDKN2B‐AS1
|
title_fullStr | A Functional Variant on 9p21.3 Related to Glioma Risk Affects Enhancer Activity and Modulates Expression of CDKN2B‐AS1
|
title_full_unstemmed | A Functional Variant on 9p21.3 Related to Glioma Risk Affects Enhancer Activity and Modulates Expression of CDKN2B‐AS1
|
title_short | A Functional Variant on 9p21.3 Related to Glioma Risk Affects Enhancer Activity and Modulates Expression of CDKN2B‐AS1
|
title_sort | functional variant on 9p21.3 related to glioma risk affects enhancer activity and modulates expression of cdkn2b‐as1 |
topic | Brief Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519084/ https://www.ncbi.nlm.nih.gov/pubmed/34153138 http://dx.doi.org/10.1002/humu.24244 |
work_keys_str_mv | AT alimouradwagdy afunctionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1 AT patrocpawank afunctionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1 AT devallmatthew afunctionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1 AT dampierchristopherh afunctionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1 AT plummersarahj afunctionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1 AT kuscucem afunctionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1 AT adlimazhar afunctionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1 AT lairosek afunctionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1 AT caseygraham afunctionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1 AT alimouradwagdy functionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1 AT patrocpawank functionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1 AT devallmatthew functionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1 AT dampierchristopherh functionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1 AT plummersarahj functionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1 AT kuscucem functionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1 AT adlimazhar functionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1 AT lairosek functionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1 AT caseygraham functionalvarianton9p213relatedtogliomariskaffectsenhanceractivityandmodulatesexpressionofcdkn2bas1 |